<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616377</url>
  </required_header>
  <id_info>
    <org_study_id>EGFR+BM</org_study_id>
    <nct_id>NCT05616377</nct_id>
  </id_info>
  <brief_title>Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation</brief_title>
  <acronym>CLTBME</acronym>
  <official_title>Survival Benefit of Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation: A Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this observational study is to learn about the survival benefit of local therapy&#xD;
      combination with target therapy in lung cancer brain metastases with EGFR mutation. The main&#xD;
      questions it aims to answer are:&#xD;
&#xD;
        -  Is local therapy performed before or after target therapy would provide survival benefit&#xD;
           ?&#xD;
&#xD;
        -  What kind of local therapy combining with target therapy would provide survival benefit,&#xD;
           neurosurgical resection or radiotherapy?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2022</start_date>
  <completion_date type="Anticipated">November 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>From date of first follow-up until the date of documented death from any cause, assessed up to 120 months</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of first follow-up until the date of first documented progression, assessed up to 120 months</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>target therapy + local therapy group vs target therapy alone group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>local therapy before target therapy group vs local therapy after target therapy group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Surgery or Radiotherapy</intervention_name>
    <description>Participants who underwent target therapy and surgery or radiotherapy were divided into target therapy + local therapy group. Participants who underwent target therapy alone were divided into target therapy alone group</description>
    <arm_group_label>target therapy + local therapy group vs target therapy alone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>before or after target therapy</intervention_name>
    <description>Participants who underwent surgery or radiotherapy before target therapy were divided into local therapy before target therapy group. Participants who underwent surgery or radiotherapy after target therapy were divided into local therapy after target therapy group.</description>
    <arm_group_label>local therapy before target therapy group vs local therapy after target therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital clients from Sun Yat-sen University Cancer Center, Guangxi Medical University&#xD;
        Cancer Hospital, The People's Hospital Of Guangxi Zhuang Autonomous Region, and the First&#xD;
        Affiliated Hospital of Guangxi Medical University will be selected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of pathological diagnosis of primary tumor.&#xD;
&#xD;
          2. Brain metastases confirmed by enhanced magnetic resonance imaging.&#xD;
&#xD;
          3. Gene test indicated that EGFR mutation.&#xD;
&#xD;
          4. Complete clinical information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. If surgical treatment is accepted, the surgical treatment is not tumor resection, but&#xD;
             ventricle puncture, biopsy and other non-tumor reducing surgery.&#xD;
&#xD;
          2. Patients with 2 or more types of tumors.&#xD;
&#xD;
          3. Incomplete clinical information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lun Liang, PHD</last_name>
    <phone>18277186779</phone>
    <email>lianglun@sysucc.org.cn</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yonggao Mou</investigator_full_name>
    <investigator_title>Department of Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

